Hypothesis

Low-molecular-weight hyaluronan (LMW-HA) fragments generated by ROS directly suppress HAS2 transcription through TLR4-dependent NF-kB signaling that induces miR-146a and recruits histone deacetylases (HDACs) to the HAS2 promoter, establishing a self-amplifying feed-forward loop that perpetuates HA loss in aged dermis and synovium.

Mechanistic Rationale

ROS-mediated cleavage converts HMW-HA (>2 MDa) into pro-inflammatory LMW-HA (<150 kDa) that acts as a DAMP via TLR2/TLR4 2 and 3. While the CF-alphavbeta3-integrin-ERK/ELK-1 pathway inhibits HAS2 in fibroblasts 1, no study has tested whether LMW-HA itself can repress HAS2. NF-kB activation is known to induce miR-146a, which targets IRAK1 and TRAF6 but also can bind the 3'-UTR of HAS2 mRNA (predicted by TargetScan). Moreover, NF-kB p65 can recruit HDAC1/2 to promoters, leading to histone deacetylation and transcriptional silencing. Thus, LMW-HA -> TLR4 -> MyD88 -> IKK -> NF-kB (nuclear) -> (i) miR-146a up-regulation -> HAS2 mRNA destabilization; (ii) HDAC recruitment -> HAS2 promoter hypoacetylation -> reduced transcription. This creates a loop: less HAS2 -> less HMW-HA -> more ROS-driven fragmentation -> more LMW-HA DAMP.

Predictions

1. In aged human dermal fibroblasts and synovial fibroblasts, exogenous LMW-HA (100 kDa) will decrease HAS2 mRNA and protein levels within 6 h, an effect blocked by TLR4 neutralizing antibody or TAK-242.
2. LMW-HA treatment will increase nuclear p65 NF-kB, up-regulate miR-146a, and increase HDAC1 occupancy at the HAS2 promoter (ChIP-qPCR).
3. Antagomir-146a or HDAC inhibitor (e.g., SAHA) will rescue HAS2 expression despite LMW-HA exposure.
4. ROS scavenging (NAC) will reduce LMW-HA generation and prevent the downstream suppression of HAS2, confirming ROS as the upstream trigger.
5. In vivo, aged mouse skin treated with intra-dermal LMW-HA will show reduced epidermal HA content, increased epidermal thickness, and elevated inflammatory cytokines, which are mitigated by topical TAK-242 or miR-146a antagomir.

Experimental Approach

• Cell culture: Isolate dermal fibroblasts from young (<=30 y) and aged (>65 y) donors; synovial fibroblasts from OA patients. Treat with 100 kDa HA (endotoxin-free) +/- TLR4 antibody, TAK-242, NAC, antagomir-146a, SAHA. Measure HAS2 mRNA (qRT-PCR), protein (Western blot, ELISA), HA secretion (HABP assay).
• Signaling: Western blot for phospho-IκB, nuclear p65; EMSA for NF-kB DNA binding.
• miRNA: qRT-PCR for miR-146a; luciferase reporter with HAS2 3'-UTR.
• Epigenetics: ChIP-qPCR for acetyl-H3K27 and HDAC1 at HAS2 promoter.
• In vivo: 18-month-old mice receive subcutaneous LMW-HA (50 µg) daily for 7 d; groups receive TAK-242 or antagomir-146a. Harvest skin, quantify HA (ELISA), histology (Masson's trichrome), cytokines (IL-6, TNF-α).

Potential Impact

Confirming a LMW-HA/TLR4/NF-kB-miR-146a/HDAC axis would reveal a novel autoregulatory circuit that explains progressive HA loss in aging tissues independent of collagen-fragment signaling. It would suggest combinatorial therapeutics—TLR4 blockade, miR-146a inhibition, or HDAC inhibition—to restore HAS2 activity and HA homeostasis in dermis, cartilage, and synovium, broadening the scope beyond antioxidant or HAS2-gene-therapy strategies.